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Brief Communication
L. G . F. Sinnige, J. W. M. van der M eer, J. W. G ratam a, J. Versteeg, F. E. Zwaan
Is Aciclovir Prophylaxis Necessary After Bone Marrow 
Transplantation?
Summary: To assess the cost-effect relationship of aci­
clovir prophylaxis versus early treatment, we perform­
ed a retrospective study in 44 allogeneic bone marrow 
transplant recipients, who had only received aciclovir 
for therapeutic purposes. After bone marrow trans­
plantation 18 herpes simplex infections occurred in 15 
of the 33 patients who were seropositive for herpes 
simplex virus. In ten patients without clinical signs, 
routine viral cultures yielded herpes simplex virus. 
Aciclovir was given intravenously to the patients with 
mucocutaneous herpes infection. All infections re­
sponded rapidly. It can be calculated that restricting 
the drug to therapeutic use reduced the amount of aci­
clovir used, which in turn diminished the cost of treat­
ment and the risk of aciclovir resistance.
Zusammenfassung: Ist nach Knochenmarkstransplan­
tation eine Aciclovir-Prophylaxe notig? Bei 44 Empfän­
gern von allogenen Knochenmarkstransplantaten, die 
Aciclovir ausschließlich therapeutisch erhalten hatten, 
wurde eine retrospektive Studie durchgeführt, um die 
Kosten-Nutzen-Beziehung für die Prophylaxe im Ver­
gleich zur Frühtherapie zu bestimmen. Bei 15 der 33 
Herpes-simplex-Virus-seropositiven Patienten traten 
nach Knochenmarkstransplantation 18 Herpes-sim- 
plex-Virus-Infektionen auf. Bei zehn klinisch sym­
ptomfreien Patienten wurde in Routinekulturen Her- 
pes-simplex-Virus nachgewiesen. Patienten mit muko­
kutaner Herpesinfektion erhielten Aciclovir intrave­
nös appliziert. Alle Infektionen sprachen rasch auf die 
Therapie an. Es läßt sich errechnen, daß eine Be­
schränkung auf den therapeutischen Einsatz des Medi­
kamentes den Verbrauch von Aciclovir vermindert 
und somit die Behandlungskosten und das Risiko der 
Resistenzentwicklung gegen Aciclovir erniedrigt.
Introduction
Following allogeneic bone marrow transplantation, 
40-80% of patients with antibodies to herpes simplex vi­
rus develop a mucocutaneous herpes simplex infection 
(1-3). In some patients, this may lead to serious complica­
tions, especially (lethal) pneumonitis. Several groups 
have reported on the efficacy of aciclovir in the preven­
tion of herpes simplex virus infections in bone marrow 
transplant recipients (2-4), while other authors have dis­
cussed earlier engraftment (5, 6) and milder grades of
acute graft versus host disease (GHVD) in patients re­
ceiving methotrexate as GHVD prophylaxis (4) in this 
context. We question the need for aciclovir prophylaxis in 
all herpes simplex virus-seropositive bone marrow trans­
plant patients in view of the effectiveness of aciclovir for 
treatment. To assess the cost-effect relationship of aciclo­
vir in bone marrow transplant patients, we performed a 
retrospective study in 44 allogeneic bone marrow trans­
plant patients who had only received aciclovir for thera­
peutic purposes.
Patients and Methods
Patients: Between September 1979 and September 1984, 44 pa­
tients were given HLA-identical, MLR-negative sibling bone 
marrow for the treatment of acute leukemia in remission 
(n = 41) or chronic myelogenous leukemia in the chronic phase 
(n = 3). The patients were prepared for transplantation as de­
scribed elsewhere (7). Engraftment was said to have occurred 
on the first day on which the number of peripheral blood neutro­
phils was greater than 0.1 x 109 cells/1. Acute GVHD was diag­
nosed and staged on the basis of the clinical criteria defined by 
Thomas et al. (8).
Diagnosis and treatment of herpes simplex virus infection: Viral 
culture of throat swabs was performed on a weekly basis during 
hospitalization, and additional cultures were taken when herpes 
simplex virus-suspect lesions appeared. Herpes simplex virus 
was isolated by inoculation of human diploid fibroblasts. Herpes 
simplex virus antibodies were determined by immune adherence 
hemagglutination (9).
Administration of aciclovir was started when mucocutaneous 
herpes simplex virus infection was suspected on clinical grounds. 
Aciclovir was given i.v. three times daily at a dosage ranging 
from 15 to 25 mg/kg/day for periods of between five and 14 
days. If necessary, the dose was adjusted to renal function ac­
cording to the regimen proposed by Blum et al. (10).
Results
Incidence o f  Herpes Simplex Virus Infection
Thirty-three of the 44 bone marrow transplant patients 
were seropositive prior to bone marrow transplant. After
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Table 1: Calculated amounts of aciclovir needed for therapy 
and prophylaxis in bone marrow transplant patients.
Indications No. of 
patients
Aciclovir 
for i.v. 
therapy (g)
Aciclovir for 
prophyJaxis (g)
i.v.* oral**
Clinical herpes 15 178 _
simplex virus
Clinical herpes simplex 22 223 -
virus and/or
positive cultures
All seropositive 33 - 743 1980
patients
All patients 44
"
990 2640
* 500 mg Aciclovir three times daily for 15 days (8);
** 400 mg Aciclovir five times daily for 30 days (11).
bone m arrow  transplant, 18 episodes of herpes simplex vi­
rus infection were diagnosed clinically in 15 of these sero­
positive patients. The m edian time of infection was 14 
days (range: 1-113 days). No infections occurred in the 
group of seronegative patients. Three patients had a sec­
ond episode of herpes simplex virus infection between 
days 69 and 86. O f the 18 herpes simplex virus episodes,
11 were confirm ed by positive cultures, The routine viral 
cultures w ere positive in seven patients w ithout clinical 
signs, the m edian time being 24 days (range: 7-127 days). 
In addition, o f the three patients who showed a four-fold 
rise in herpes simplex virus antibody tite r, two had nega­
tive cultures and no clinical signs of herpes simplex virus 
infection. O nly one patient developed a generalized h er­
pes simplex virus infection o f the skin; in this case aciclo­
vir therapy led to a com plete recovery. N one of the her­
pes simplex virus infections resulted in a fatal outcom e in 
this series.
Therapy with Aciclovir
Of the 18 episodes of clinically diagnosed herpes simplex 
virus infection, 15 were trea ted  with aciclovir during a 
median period of seven days (range: 5-14 days). The m e­
dian total am ount of aciclovir given per patient was 7 g 
(range: 3 .5-20 g). All patients showed regression of the 
lesions within six days after the  initiation of therapy. Aci­
clovir was no t given during three of the episodes because 
the drug was not readily available at the tim e; all three 
ended in spontaneous recovery.
Calculation o f  the Total Amounts o f Aciclovir
We calculated the am ount of aciclovir that would have 
been given during the first 40 days following bone m arrow 
transplant, e ither for treatm ent or as prophylaxis in her­
pes simplex virus infection (Table 1). In the present study 
our patients received 148 g aciclovir during the first 40 
days after bone marrow transplant. If we take  into ac­
count the th ree  episodes that were not trea ted  because of 
a tem porarily  limited supply of aciclovir, this am ount 
would have been  178 g. H ad all 33 seropositive patients 
been treated  with aciclovir prophylactically according to 
the regim ens proposed by Saral et al. (2) o r Wade et al.
(6), the am ount of aciclovir given would have been  four 
or eleven tim es greater, respectively.
Influence o f  Aciclovir on Engraftment
The m edian tim e to engraftm ent was 13 days (range: 7-27 
days). In 36 patients who did  not receive aciclovir before 
engraftm ent, the median tim e to engraftm ent was 13 days 
(range: 7-20 days), and in eight patients given aciclovir 
before engraftm ent the m edian time was also 13 days 
(range: 11-27 days; p = 0.3, W ilcoxon’s rank test).
Influence o f Aciclovir on Acute GVHD
Of the 44 patients, 31 developed G V H D . Two patients 
could not be evaluated because they died within a m onth 
after bone m arrow  transplantation, but w ithout evidence 
of G V H D . O f the patients who received aciclovir in the 
first m onth after bone m arrow  transplantation (n =  12), 
five had grade 0-1 G V H D . The m edian tim e of onset of 
G V H D  in these 12 patients was day 30 (range: 18-54 
days). Thirty patients did not receive aciclovir in the first 
month post-bone marrow transplant; ten of these did not 
develop G V H D , and three developed only grade I (days 
of onset: 7, 32 and 33). Seventeen patients showed severe 
G H V D  (grade II—IV) after a m edian tim e of 25 days 
(range: 16-36 days) after bone marrow transplant (x2 =  
0.01, p = 0.9367).
Discussion
In this study, 75% of the 44 bone m arrow transplant pa­
tients were seropositive for herpes simplex virus. D uring 
the first 40 days post-bone m arrow transplant, clinically 
diagnosed herpes simplex virus infection occurred in 47% 
of the seropositive patients and in none of the seronega­
tive patients. The incidence o f recurrence of herpes sim­
plex virus in treated  patients is lower for ou r series than in 
those of o thers (2, 4, 6), who reported 73% , 82% and 
80% , respectively. In our series, herpes simplex virus in­
fections were rem arkably free of complications. G eneral­
ization was observed in one patient, but organ involve­
ment did not occur. Since we did see com plications of 
herpes simplex virus infection in the pre-aciclovir e ra , it 
seems probable that early aciclovir therapy is capable of 
preventing them . It has been reported tha t aciclovir pro­
phylaxis tends to lessen the severity of G H V D  (4) and to 
prom ote engraftm ent (6). In  our study we found no evi­
dence to  indicate milder G H V D  or earlier engraftm ent in 
patients given aciclovir in the first m onth after bone m ar­
row transplantation . H ow ever, our patients received aci­
clovir later and over a shorter period of tim e than those of 
Gluckman et al. and Wade e t al. On the basis o f our expe­
rience, we consider it unnecessary to give aciclovir p ro ­
phylaxis to seropositive bone marrow transplant patients. 
O ur calculations show that restricting the drug to th era­
peutic use reduced the am ount of aciclovir used, which in 
turn dim inished not only the cost of trea tm en t but also the 
risk of aciclovir resistance (11).
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